Cancer treatment using BMP inhibitor
View Patent ↗Methods for regulating cancer cell growth and survival, inhibiting cancer cell growth, promoting cancer cell death, and/or treating a cancer make use of antagonists of a type I BMP receptor. In some embodiments the cancer is a lung cancer and the cancer cell is a lung cancer cell.
1. A method of inhibiting cancer cell growth and/or promoting cancer cell death, comprising: administering to a cancer cell an effective amount of an antagonist of a type I BMP receptor, wherein the antagonist of a type I BMP receptor is a compound of the formula:
or pharmaceutically-acceptable salt thereof,
wherein R 1 is selected from the group consisting of alkyl, branched alkyl, substituted alkyl, aryl, substituted aryl, alkoxy, amino, and dialkylamino; and
wherein R 2 is selected from the group consisting of
wherein the cancer cell is a lung cancer cell.
2. The method of claim 1 , wherein R 1 is selected from the group consisting of
and
wherein R 2 is selected from the group consisting of
3. The method of claim 1 , wherein the antagonist is a compound of the formula:
4. The method of claim 1 , wherein the antagonist is a compound of the formula:
5. The method of claim 1 , wherein the antagonist is a compound of the formula:
6. The method of claim 1 , wherein the cancer cell is in a subject in need of treatment for a lung cancer, and the effective amount of the antagonist of a type I BMP receptor is administered to the subject for the treatment of the lung cancer.
7. The method of claim 6 , and further comprising administering an anti-cancer agent and/or radiation to the subject.
8. A kit for inhibiting cancer cell growth and/or promoting cancer cell death, comprising: an antagonist of a type I BMP receptor; and a device for administering the BMP inhibitor, wherein the antagonist of a type I BMP receptor is a compound selected from the group consisting of
9. A method of inhibiting cancer cell growth and/or promoting cancer cell death, comprising: administering to a cancer cell an effective amount of an antagonist of a type I BMP receptor, wherein the antagonist of a type I BMP receptor is a compound selected from the group consisting of
10. The method of claim 9 , wherein the antagonist is a compound of the formula:
11. The method of claim 9 , wherein the antagonist is a compound of the formula:
12. The method of claim 9 , wherein the antagonist is a compound of the formula:
13. The method of claim 9 , wherein the cancer cell is in a subject in need of treatment for a cancer, and the effective amount of the antagonist of a type I BMP receptor is administered to the subject for the treatment of the cancer.
14. The method of claim 13 , and further comprising administering an anti-cancer agent and/or radiation to the subject.